Literature DB >> 17018738

Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.

A Hochhaus1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17018738     DOI： 10.1093/annonc/mdl273

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  12 in total

1.  Dual-inhibitors of STAT5 and STAT3: studies from molecular docking and molecular dynamics simulations.

Authors:  Shengjuan Shao; Rilei Yu; Yanqing Yu; Yanni Li
Journal:  J Mol Model       Date:  2014-08-07       Impact factor: 1.810

2.  ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.

Authors:  Stephany Corrêa; Renata Binato; Bárbara Du Rocher; Gerson Ferreira; Paola Cappelletti; Sheila Soares-Lima; Luis Felipe Pinto; André Mencalha; Eliana Abdelhay
Journal:  Epigenetics       Date:  2014-07-02       Impact factor: 4.528

Review 3.  Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Authors:  Ami B Patel; Thomas O'Hare; Michael W Deininger
Journal:  Hematol Oncol Clin North Am       Date:  2017-08       Impact factor: 3.722

4.  Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.

Authors:  Adam Olshen; Min Tang; Jorge Cortes; Mithat Gonen; Timothy Hughes; Susan Branford; Alfonso Quintás-Cardama; Franziska Michor
Journal:  Haematologica       Date:  2014-09-12       Impact factor: 9.941

5.  Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.

Authors:  Stephany Corrêa; Renata Binato; Bárbara Du Rocher; Morgana T L Castelo-Branco; Luciana Pizzatti; Eliana Abdelhay
Journal:  BMC Cancer       Date:  2012-07-23       Impact factor: 4.430

6.  Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.

Authors:  Kevin Leder; Jasmine Foo; Brian Skaggs; Mercedes Gorre; Charles L Sawyers; Franziska Michor
Journal:  PLoS One       Date:  2011-11-28       Impact factor: 3.240

7.  A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line.

Authors:  Stephany Corrêa; Luciana Pizzatti; Bárbara Du Rocher; André Mencalha; Daniela Pinto; Eliana Abdelhay
Journal:  Proteome Sci       Date:  2012-03-30       Impact factor: 2.480

Review 8.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

9.  Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Abdul Aziz Baba; Azlan Husin; Abu Dzarr Abdullah; Rosline Hassan; Goh Ai Sim; S Fadilah Abdul Wahid; Ravindran Ankathil
Journal:  Hematol Rep       Date:  2012-11-23

10.  HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Abdul Aziz Baba; Azlan Husin; Sarina Sulong; Rosline Hassan; Goh Ai Sim; S Fadilah Abdul Wahid; Ravindran Ankathil
Journal:  Biomed Res Int       Date:  2012-12-26       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.